Showing 176–200 of 200 documents
Sorted by hybrid relevance (keyword + semantic via RRF)
Gao L, Zhang H, Xin H, Liu J, Pan S, et al.
… Registry identifier ChiCTR-IOR-15007202), two short-course regimens with rifapentine plus isoniazid (a 3-month once-weekly regimen and a 2-month twice-weekly regimen) were initially designed to be evaluated for rural residents aged 50-69 years with LTBI in China.Due to the incre…
Fekadu G, Wang Y, You JHS
BACKGROUND: Recent clinical findings reported improvement in the treatment outcomes of highly resistant TB (HDR-TB) with the pretomanid (Pa) based regimen. This study aimed to evaluate the cost-effectiveness of the Pa-based regimen for HDR-TB treatment from the perspective of the…
Lin YJ, Lin HC, Yang YF, Chen CY, Lu TH, et al.
…logical impact and cost-effectiveness of shorter antibiotic regimens in high tuberculosis (TB) burden regions of Taiwan. Methods This study combined the TB population dynamic model and cost-effectiveness analysis with local data to simulate the disease burdens, effectiveness and …
Wheeler C, Mohle-Boetani J
…16%) than among nonincarcerated persons (6%). We compared 2 regimens to treat LTBI in an adult prison population in California: 9 months of twice-weekly isoniazid (9H; previous standard of care) and 12 once-weekly doses of isoniazid and rifapentine (3HP; introduced in 2011). Meth…
Chin-Chung Shu
…emains unclear. Currently, three-month rifamycin-containing regimens, such as weekly rifapentine and isoniazid (3HP) or daily rifampicin and isoniazid (3HP), are common because its non-inferiority to nine-month of daily isoniazid (9H) and high completion rate by its short course …
Sha wei
…e public health burden.Research on optimal drug combination regimens to further shorten the duration and improve the efficacy of multidrug-resistant tuberculosis treatment is an important research direction.The PRS (parabolic response surface, FSC.II) system is an enhanced use of…
Stephanie Palacios, Glenford Refre, Patricio Palmes, Ma. Cecilia Momville
…abases, comparing the 4-month and 6-month anti-TB treatment regimens. RCTs that were published in the English language from 2017-2022 that used drug susceptible TB adult patients were included in the final meta-analysis. We compared the efficacy and safety of the two regimens usi…
Muhammad Rifqy Alvy Widodo, Ida Srisurani Wiji Astuti, Inke Kusumastuti, Angga Mardro Raharjo, Supangat Supangat, et al.
… comparison between the administration of individual MDR-TB regimens and short-term regimens concerning anxiety levels in MDR-TB patients at Dr. Soebandi Regional General Hospital, Jember. Methods: This was an analytical observational study with a cross-sectional design. It was c…
Yohanes Widjaja, Khairuddin Djawad, Saffruddin Amin, Widyawati Djamaluddin, Dirmawati Kadir, et al.
Abstract Introduction . Leprosy is a disease that predominantly affects the skin and peripheral nerves, resulting in neuropathy and associated long-term consequences, including deformities and disabilities. According to the WHO classification, there are two categories of leprosy,…
Musfardi Rustam, Ratna Djuwita, Sudarto Ronoatmodjo, Erlina Burhan, Evi Martha, et al.
…ster on the 272 th day. The risk of T2DM group with the new regimens in the treatment of DR-TB was 10.66 times (95% CI 3.23-35.12). Whereas, the treatment on NonT2DM group with old regimen with marital status that was controlled showed a significant statistic value with value p&l…
Yu. I. Feshchenko, N.А. Lytvynenko, M.V. Pohrebna, Yu.О. Senko, Anastasiia Lafeta, et al.
Objective — to study the programmatic results of the efficacy and tolerability of the standard combination BPaL regimen for patients with multidrug-resistant tuberculosis failures and pre-XDR-TB. Materials and methods. Treatment of patients with BPaL regimen took place within th…
Preethi Koyyana, Mohana Pradeepika Machcha, Rajasekharam Gunta, Dhilleswara Rao Pudi
… reduction of social stigmatization. In contrast to earlier regimens that contained injectable drugs, the World Health Organization has recommended all-oral regimens for the treatment of Multidrug-Resistant/Rifampicin-Resistant-TB since 2018, which represents a significant advanc…
Jyoti Bajpai, Darshan Kumar Bajaj, Sandeep Kumar, Rashmi Kushwaha, Surya Kant, et al.
…fication test)&LPA(Line Probe Assay)and availability of regimens with duration of 9-11months in contrast to previous lengthy regimens things have become better. Present study was undertaken to study microbiological conversion and adverse effect profile of shorter regimen <b>M…
Van Deun A, Decroo T, Kya Jai Maug A, Hossain MA, Gumusboga M, et al.
…two months), but had little impact on rifampicin-throughout regimens: (6 months, new cases; 3.8%; OR 0.8, 95%CI:0.3,2.8; 8 months, retreatment cases: 7.3%, OR 1.8; 95%CI:1.3,2.6). Rr was missed in 7.6% of randomly selected "Hr" strains. Acquired Rr was frequent among recurrences …
Van Deun A, Decroo T, Piubello A, de Jong BC, Lynen L, et al.
…th Organization guidelines for the formulation of treatment regimens for multidrug-resistant tuberculosis (MDR-TB) pay too little attention to the microbiological activity of anti-tuberculosis drugs. Here, we draw lessons from the pioneering work done on shorter MDR-TB treatment …
Song L, Zhang Y, Sun F, Lan Y, Tong J, et al.
…atment have led to concerns about hepatotoxicity in shorter regimens. We evaluated hepatotoxicity in two novel regimens against the standard shorter regimen recommended by the World Health Organization (WHO). Methods Participants from the TB-TRUST and TB-TRUST plus trials were as…
Jorge Torresi, Ana Angélica Bulcão Portela Lindoso
…lable drugs. The recent implementation of bedaquiline-based regimens represents an advance in combating this condition, although few studies have evaluated the public health impact of their implementation. The present study aimed to evaluate the impacts of implementing oral regim…
Feng Sun, Yang Li, Yilin Zhang, Cui Cai, Yuanyuan Chen, et al.
**OBJECTIVES:** Despite advancements in shorter, oral regimens for drug-resistant tuberculosis, more options are needed to extent patient benefits. We conducted a trial to evaluate the noninferiority of an all-oral regimen compared with the injectable-containing regimen. **METHO…
Ardhianto D, Suharjono, Soedarsono, Fatmawati U
…ion. The aim was to study the differences in the use of BDQ regimens to the lengthening of the QTc interval and to study risk factors (diabetes, hypokalemia, sex, BMI, and age) in BDQ regimen. Methods This study was an observational retrospective study with a total sampling metho…
Arinaminpathy N, Gomez GB, Sachdeva KS, Rao R, Parmar M, et al.
…re is increasing interest in future, highly-potent 'pan-TB' regimens against tuberculosis (TB), that may be equally effective in both drug-susceptible and rifampicin-resistant (RR) forms of TB. Taking the example of India, the country with the world's largest burden of TB, we sho…
Modongo C, Wang Q, Dima M, Matsiri O, Kgwaadira B, et al.
… patients concomitantly receiving rifampicin- and DTG-based regimens under programmatic conditions in Botswana. The outcomes of interest were successful TB treatment and viral load suppression. We used multivariable logistic models to determine predictors for each outcome of inte…
Rais M, Abdelaal H, Reese VA, Ferede D, Larsen SE, et al.
…me/boost regimen. More significantly, among all the vaccine regimens tested only repRNA-ID91/ID91+GLA-SE induced IFN-γ and TNF-secreting CD8 + T cells. Furthermore, the repRNA-ID91/ID91+GLA-SE vaccine strategy elicited high systemic proinflammatory cytokine responses and induced …
Rodriguez CA, Lodi S, Horsburgh CR, Mitnick CD, Bastard M, et al.
Clarity about the role of delamanid in longer regimens for multidrug-resistant TB is needed after discordant Phase IIb and Phase III randomized controlled trial results. The Phase IIb trial found that the addition of delamanid to a background regimen hastened culture conversion; …
Avaliani T, Sereda Y, Davtyan H, Tukvadze N, Togonidze T, et al.
Tuberculosis treatment is challenging, especially among people with drug-resistant forms of tuberculosis. The introduction of fully oral modified short treatment regimen has a great potential to shorten duration of treatment, improve safety and ultimately increase treatment succe…
Gualano G, Musso M, Mencarini P, Mosti S, Cerva C, et al.
… of MDR-TB has been revolutionized by all oral anti-TB drug regimens that are likely to improve adherence and treatment outcomes. These regimes include bedaquiline (B), pretomanid (P), and linezolid (L) (BPaL), and moxifloxacin if resistance to fluoroquinolones is not detected (B…